Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study
Su Jin Jeong, Seung Eun Lee, Dong Hyun Shin, et al.
BMC Nephrology (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Development and Validation of Prediction Models of Adverse Kidney Outcomes in the Population With and Without Diabetes
Morgan E. Grams, Nigel J. Brunskill, Shoshana H. Ballew, et al.
Diabetes Care (2022) Vol. 45, Iss. 9, pp. 2055-2063
Open Access | Times Cited: 38
Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies
Aftab Ahmad, Hani Sabbour
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 10
Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes
Christine P. Limonte, Yoshio N. Hall, Subbulaxmi Trikudanathan, et al.
Journal of Diabetes and its Complications (2022) Vol. 36, Iss. 6, pp. 108204-108204
Open Access | Times Cited: 32
Practical considerations for the use of SGLT‐2 inhibitors in the Asia–Pacific countries—An expert consensus statement
Adrian Liew, Aida Lydia, Bien J. Matawaran, et al.
Nephrology (2023) Vol. 28, Iss. 8, pp. 415-424
Open Access | Times Cited: 17
Sodium‐glucose co‐transporter‐2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice
Kamlesh Khunti, Serge Jabbour, Xavier Cos, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 7, pp. 1187-1196
Open Access | Times Cited: 26
Re-evaluating national screening for chronic kidney disease in the UK
Vageesh Jain, Smeeta Sinha, Catriona Shaw, et al.
BMJ (2023), pp. e074265-e074265
Closed Access | Times Cited: 12
Prescribing patterns of SGLT-2 inhibitors and their association with heart failure readmissions: a single-center cross-sectional study from a low- and middle-income country
Abrar Ali Chhachhar, Saadia Sattar, Farhala Baloch, et al.
Hospital Practice (2025) Vol. 53, Iss. 1
Closed Access
Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk
André Scheen
Diabetes Epidemiology and Management (2023) Vol. 13, pp. 100184-100184
Open Access | Times Cited: 9
Effects of Dapagliflozin in Chronic Kidney Disease Across the Spectrum of Age and by Sex
Margaret K. Yu, Priya Vart, Niels Jongs, et al.
Journal of General Internal Medicine (2023) Vol. 39, Iss. 6, pp. 921-930
Open Access | Times Cited: 9
Real-World Treatment Patterns according to Clinical Practice Guidelines in Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Korea: Multicenter, Retrospective, Observational Study
Ye Yang, Nam Hoon Kim, Jong Ha Baek, et al.
Diabetes & Metabolism Journal (2024) Vol. 48, Iss. 2, pp. 279-289
Open Access | Times Cited: 3
A review of the latest real‐world evidence studies in diabetic kidney disease: What have we learned about clinical practice and the clinical effectiveness of interventions?
Fabrice Bonnet, Mark E. Cooper, Laetitia Koppe, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. S6, pp. 55-65
Open Access | Times Cited: 2
Novel Therapies for Kidney Disease in People With Diabetes
Nayana Khurana, Steven James, Melinda T. Coughlan, et al.
The Journal of Clinical Endocrinology & Metabolism (2021) Vol. 107, Iss. 1, pp. e1-e24
Open Access | Times Cited: 16
Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk
Clare Arnott, Robert A. Fletcher, Bruce Neal
Heart Failure Clinics (2022) Vol. 18, Iss. 4, pp. 645-654
Closed Access | Times Cited: 12
Factors affecting prescription of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus with established cardiovascular disease/ chronic kidney disease in Hong Kong: a qualitative study
Ngai Mui Ng, Yeung Shing Ng, Tsun Kit Chu, et al.
BMC Primary Care (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 11
Inadequate Use of Newer Treatments and Glycemic Control by Cardiovascular Risk and Sociodemographic Groups in US Adults with Diabetes in the NIH Precision Medicine Initiative All of Us Research Program
Divya Devineni, Meleeka Akbarpour, Yufan Gong, et al.
Cardiovascular Drugs and Therapy (2022) Vol. 38, Iss. 2, pp. 347-357
Open Access | Times Cited: 10
Cardiovascular and renal outcomes with SGLT2 inhibitors: Real-life observational studies in older patients with type 2 diabetes
André Scheen
Diabetes Epidemiology and Management (2023) Vol. 10, pp. 100135-100135
Open Access | Times Cited: 5
Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosis
Vandana Mathur, David A. Bushinsky, Lesley A. Inker, et al.
Nephrology Dialysis Transplantation (2022) Vol. 38, Iss. 6, pp. 1448-1458
Open Access | Times Cited: 8
Relationship between dapagliflozin and urinary albumin-to-creatinine ratio in patients with diabetes mellitus and cardiovascular disease: an observational study
Zejia Wu, Xuyu He, Shuang Xia, et al.
Cardiology Plus (2023) Vol. 8, Iss. 4, pp. 263-268
Open Access | Times Cited: 4
Kidney and cardiovascular-protective benefits of combination drug therapies in chronic kidney disease associated with type 2 diabetes
Muhammad Shahzeb Khan, Janice P. Lea
BMC Nephrology (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Barriers to early diagnosis of chronic kidney disease and use of sodium‐glucose cotransporter‐2 inhibitors for renal protection: A comprehensive review and call to action
Leszek Czupryniak, Ofri Mosenzon, Ivan Rychlík, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 10, pp. 4165-4177
Open Access | Times Cited: 1
Increasing Societal Benefit From Cardiovascular Drugs
Marcello Tonelli, Sharon E. Straus
Circulation (2022) Vol. 146, Iss. 21, pp. 1627-1635
Open Access | Times Cited: 6
The Role of Sodium-Glucose Cotransporter-2 Inhibitors in the Treatment Paradigm of CKD in Africa: An African Association of Nephrology Panel Position Paper
F. Jarraya, Abdou Niang, Hussein Bagha, et al.
Kidney International Reports (2023) Vol. 9, Iss. 3, pp. 526-548
Open Access | Times Cited: 3
Identifying Barriers and Facilitators for Increasing Uptake of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in British Columbia, Canada, using the Consolidated Framework for Implementation Research
Tae Won Yi, Daniel V. O’Hara, Brendan Smyth, et al.
Canadian Journal of Kidney Health and Disease (2023) Vol. 11
Open Access | Times Cited: 3
Cardiovascular Disease Assessment Prior to Kidney Transplantation
Elise C. Ewing, Angelina Edwards
Methodist DeBakey Cardiovascular Journal (2022) Vol. 18, Iss. 4, pp. 50-61
Open Access | Times Cited: 5
Sodium Glucose Co-Transporter 2 Inhibitors and the Cardiovascular System: Current Knowledge and Future Expectations
Ioannis Boutsikos, Eleftherios Beltsios, Bastian Schmack, et al.
Heart International (2023) Vol. 17, Iss. 2, pp. 12-12
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top